Last reviewed · How we verify
HP-802-247
HP-802-247 is a monoclonal antibody targeting CD47.
HP-802-247 is a monoclonal antibody targeting CD47. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | HP-802-247 |
|---|---|
| Sponsor | Healthpoint |
| Drug class | CD47 antibody |
| Target | CD47 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CD47 is a protein that inhibits phagocytosis, and blocking it can stimulate the immune system to attack cancer cells. HP-802-247 works by binding to CD47 and preventing it from interacting with its receptor, SIRPα, which is found on the surface of immune cells.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Safety Follow-Up to HP 802-247-09-015
- Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients (PHASE2)
- Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |